Jessica I Goldberg1, Debra A Goldman2, Sarah McCaskey1, Douglas J Koo3, Andrew S Epstein3. 1. Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
PURPOSE: Malignant bowel obstruction (MBO) is common in advanced GI cancer, and MBO management, including drainage percutaneous endoscopic gastrostomy (dPEG), is palliative. How patients understand the goals of dPEG and its impact on disease is inadequately understood in the literature. Therefore, we analyzed these issues in patients with GI cancer. METHODS: Demographics, clinical variables, and patient outcomes were abstracted from the medical record. Illness understanding and future expectations were retrieved from palliative care notes. We described additional treatment and outcomes after dPEG and estimated overall survival (OS). RESULTS: From January 2015 to June 2017, 125 admitted patients with metastatic GI cancer underwent dPEG for MBO. Cancers were most commonly colorectal (34%) and pancreatic/ampullary (25%). During the dPEG admission, 32% (40 of 125) of patients had a palliative care consultation, and 22% (28 of 125) were asked about illness understanding and future expectations. All (28 of 28) reported good understanding of the advanced nature of their disease, but few were accurate about prognosis given their stage IV disease (10 of 28). Of the 117 (94%) discharged, 13% (15 of 117) received additional chemotherapy, which rarely prevented progression; half (63 of 117) had a do-not-resuscitate order; and most (101 of 117) were enrolled in hospice at death. Median time to death was 37 days (95% CI, 29 to 45 days); 6-month OS was 3.7% (95% CI, 1.2% to 8.4%). CONCLUSION: dPEGs are placed close to end of life in patients with advanced GI cancer. A minority of patients receive additional chemotherapy post-dPEG. Many have adequate disease understanding, but chemotherapy benefit is low, and future expectations vary. This may be an opportunity for improved communication regarding palliative procedures in advanced cancer.
PURPOSE: Malignant bowel obstruction (MBO) is common in advanced GI cancer, and MBO management, including drainage percutaneous endoscopic gastrostomy (dPEG), is palliative. How patients understand the goals of dPEG and its impact on disease is inadequately understood in the literature. Therefore, we analyzed these issues in patients with GI cancer. METHODS: Demographics, clinical variables, and patient outcomes were abstracted from the medical record. Illness understanding and future expectations were retrieved from palliative care notes. We described additional treatment and outcomes after dPEG and estimated overall survival (OS). RESULTS: From January 2015 to June 2017, 125 admitted patients with metastatic GI cancer underwent dPEG for MBO. Cancers were most commonly colorectal (34%) and pancreatic/ampullary (25%). During the dPEG admission, 32% (40 of 125) of patients had a palliative care consultation, and 22% (28 of 125) were asked about illness understanding and future expectations. All (28 of 28) reported good understanding of the advanced nature of their disease, but few were accurate about prognosis given their stage IV disease (10 of 28). Of the 117 (94%) discharged, 13% (15 of 117) received additional chemotherapy, which rarely prevented progression; half (63 of 117) had a do-not-resuscitate order; and most (101 of 117) were enrolled in hospice at death. Median time to death was 37 days (95% CI, 29 to 45 days); 6-month OS was 3.7% (95% CI, 1.2% to 8.4%). CONCLUSION: dPEGs are placed close to end of life in patients with advanced GI cancer. A minority of patients receive additional chemotherapy post-dPEG. Many have adequate disease understanding, but chemotherapy benefit is low, and future expectations vary. This may be an opportunity for improved communication regarding palliative procedures in advanced cancer.
Authors: Lisa D DiMartino; Bryan J Weiner; Laura C Hanson; Morris Weinberger; Sarah A Birken; Katherine Reeder-Hayes; Justin G Trogdon Journal: J Palliat Med Date: 2017-08-03 Impact factor: 2.947
Authors: Kimberly Moore Dalal; Marc J Gollub; Thomas J Miner; W Douglas Wong; Hans Gerdes; Mark A Schattner; David P Jaques; Larissa K F Temple Journal: J Palliat Med Date: 2011-05-19 Impact factor: 2.947
Authors: Rachel B Issaka; David M Shapiro; Neehar D Parikh; Mary F Mulcahy; Srinadh Komanduri; John A Martin; Rajesh N Keswani Journal: Surg Endosc Date: 2013-12-24 Impact factor: 4.584
Authors: Megan Winner; Stephen J Mooney; Dawn L Hershman; Daniel L Feingold; John D Allendorf; Jason D Wright; Alfred I Neugut Journal: Dis Colon Rectum Date: 2013-07 Impact factor: 4.585
Authors: Elizabeth J Lilley; John W Scott; Joel E Goldberg; Christy E Cauley; Jennifer S Temel; Andrew S Epstein; Stuart R Lipsitz; Brittany L Smalls; Adil H Haider; Angela M Bader; Joel S Weissman; Zara Cooper Journal: Ann Surg Date: 2018-04 Impact factor: 13.787